News | December 16, 2021
Syngene extends contract with Amgen till 2026
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
While continuing to offer its current breadth of genomic services, Biogazelle will become CellCarta's Center of Excellence for the development of complex genomic biomarker assays
FDA changes inspection classification of the facility to Voluntary Action Indicated
_256_384.jpg)
In Japan, breast cancer is the most common cancer in women, with approximately 92,000 cases of breast cancer diagnosed in 2020
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.
Fujifilm India will be providing healthcare Imaging devices and equipment’s to increase the standards of the veterinary care in India.
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
The first hospital in Kharadi launched three years ago has made a significant difference to women and children's health
The company has also started working with a large pharma company on the API supply of a recently launched animal and human health product
Subscribe To Our Newsletter & Stay Updated
